KaydedilenlerDerginizi ekleyin

Dergiler / Klinik Psikofarmakoloji Bülteni / 2002 / Cilt: 12 - Sayı: 1

Nefazodone versus sertraline in treatment of posttraumatic stress disorder

Melek Z. SAYGIN
Mehmet Z. SUNGUR
Esin U. SABOL
Pelin ÇETİNKAY
Sayfa
1–5
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

There were significant differences between initial and endpoint TOP-8 and CGI scores (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Nefazadone is an antidepressant that have a dual effect on serotonergic transmission by acting as both a reuptake inhibitor presynaptically and an antagonist at 5-HT2A receptor postsynapticaily.
📊
Temel Bulgular & Veri:Some authors have suggested that the 5-HT2A receptor may be involved in the pathophysiology of posttraumatic stress disorder (PTSD).
💡
Sonuç & Katkı:There were significant differences between initial and endpoint TOP-8 and CGI scores (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Nefazadone is an antidepressant that have a dual effect on serotonergic transmission by acting as both a reuptake inhibitor presynaptically and an antagonist at 5-HT2A receptor postsynapticaily. Some authors have suggested that the 5-HT2A receptor may be involved in the pathophysiology of posttraumatic stress disorder (PTSD). In this study , the efficacy of nefazodone in treatment of PTSD was investigated in comparison to the efficacy of sertraline. Methods: Subjects were randomly assigned to two treatment groups, nefazodone or sertraline group. Sixty subjects were recruited with 30 subjects in each treatment group. PTSD patients were diagnosed by using the Structured Clinical Interview for DSM-IV (SCID-1) and nonstructured psychiatric interview. Measurements have been made every month for a five-months period with six assessment points including the baseline. Primary outcome measures consisted of the Posttraumatic Stress Diagnostic Scale (PDS), the eight-item Treatment-outcome Posttraumatic Stress Disorder Scale (TOP-8), Clinical Global Impression Scale (CGI) ratings. Results: The subjects in both of these groups had significantly improved. There were significant differences between initial and endpoint TOP-8 and CGI scores (p

🔖

Bu Makaleye Atıf Yap

SAYGIN, M. Z., SUNGUR, M. Z., SABOL, E. U., ÇETİNKAY, P. (2022). Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Klinik Psikofarmakoloji Bülteni, Cilt: 12 - Sayı: 1, 1–5. https://ajindex.com/articles/574518

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995; 52:1048-1060
  2. Solomon SD, Davidson JR. Trauma: prevalence, impairment, service use and cost. J Clin Psychiatry 1997; 58:5-11
  3. Zatzick DF, Marmar CR, Weiss DS, Browner WS, Metzler TJ, Golding JM, Stewart A, Schlenger WE, Wells KB. Posttraumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans. Am J Psychiatry 1997; 154:1690-1695
  4. Foa EB, Davidson JRT, Frances AJ. Treatment of PTSD(Expert Consensus Guideline) J Clin Psychiatry 1999; Vol.60, supp.10 5. Davidson JRT, Weisler RH, Malik ML, Connor MK.Treatment of PTSD with nefazodone. Int Clin Psychopharmacol 1998; 13:1.11-3
  5. Davis LL, Nugent A, Murray J, Kramer G, Petty F. Nefazodone treatment for chronic PTSD: an open trial J Clin Psychopharmacol 2000; 20:159-164
  6. Hertzberg MA, Feldman ME,. Beckham JC, Moore SD, Davidson JRT. Open trial of nefazodone for combat-related PTSD. JCliri Psychiatry 1998; 59:460-4
  7. Hidalgo RB, Hertzberg MA, 'Mellman TA, Petty F, Phebe T. Nefazodone in PTSD: results from six open-label trials. Int. Clin Psychopharmacol 1999; 14:61-68
  8. Food and Drug Administration. Consideration of NDA(1999) 19-839: Sertraline Hydrochloride:Proposed indication: treatment of PTSD. Transcript of meeting of Psychopharmacologic Drugs Advisory Committee, Oct 8. Available from: URLwww.fda.gov/ohrms/dockets
  9. Alison MC, David PF. Sertraline, a review of its therapeutic use in PTSD. CNS Drugs 2000; 14:391-407
  10. Foa EB, Cashman L, Jaycox L, Perry K. The validation of a self- report measure of posttraumatic stress disorder, the posttraumatic diagnostic scale. Psychol Assessment 1997; 9:445-51
  11. Davidson JRT, Colket JT. The eigth-item treatment-outcome PTSD scale. Int Clin Psychopharmacol 1997; 12:41-5
  12. ECDEU Assessment Manual for Psychopharmacology Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976
  13. Davidson JRT. Posttraumatic Stress Disorder. In: Nutt D. Editor. Treatment outcome PTSD Scale. Martin Dunitz Ltd. London, 2000; p 132, 209, 243-244.